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OBJECTIVES This study was designed to test the hypothesis that epinephrine infusion may be a provocative
test able to unmask nonpenetrant KCNQ1 mutation carriers.
BACKGROUND The LQT1 form of congenital long QT syndrome is associated with high vulnerability to
sympathetic stimulation and appears with incomplete penetrance.
METHODS The 12-lead electrocardiographic parameters before and after epinephrine infusion were
compared among 19 mutation carriers with a baseline corrected QT interval (QTc) of 460
ms (Group I), 15 mutation carriers with a QTc of 460 ms (Group II), 12 nonmutation
carriers (Group III), and 15 controls (Group IV).
RESULTS The mean corrected Q-Tend (QTce), Q-Tpeak (QTcp), and Tpeak-end (Tcp-e) intervals
among 12-leads before epinephrine were significantly larger in Group I than in the other
three groups. Epinephrine (0.1 g/kg/min) increased significantly the mean QTce, QTcp,
Tcp-e, and the dispersion of QTcp in Groups I and II, but not in Groups III and IV. The
sensitivity and specificity of QTce measurements to identify mutation carriers were 59%
(20/34) and 100% (27/27), respectively, before epinephrine, and the sensitivity was substan-
tially improved to 91% (31/34) without the expense of specificity (100%, 27/27) after
epinephrine. The mean QTce, QTcp, and Tcp-e before and after epinephrine were
significantly larger in 15 symptomatic than in 19 asymptomatic mutation carriers in Groups
I and II, and the prolongation of the mean QTce with epinephrine was significantly larger in
symptomatic patients.
CONCLUSIONS Epinephrine challenge is a powerful test to establish electrocardiographic diagnosis in silent
LQT1 mutation carriers, thus allowing implementation of prophylactic measures aimed at
reducing sudden cardiac death. (J Am Coll Cardiol 2003;41:633–42) © 2003 by the
American College of Cardiology Foundation
Recent evidence has suggested that cardiac events associated
with sympathetic stimulation are more common among the
LQT1 form than the LQT2 or LQT3 forms of congenital
long QT syndrome (LQTS) (1–4). LQT1 is one of the two
most common genetic form of LQTS so far identified, and
is frequently manifest with variable expressivity and incom-
plete penetrance (5). Because molecular diagnosis is still
unavailable to many clinical centers, and it requires high
costs and a long time to be performed, there is a strong need
to devise clinical tools to improve the sensitivity of clinical
tests to establish the diagnosis of LQTS. Infusion of
catecholamines, such as epinephrine or isoproterenol, has
been used to unmask patients with suspected LQTS (6).
Recent clinical data from our group and others have
demonstrated the differential response of dynamic QT
interval to epinephrine infusion in LQT1, LQT2, and
LQT3 syndrome and the paradoxical QT prolongation in
LQT1 syndrome (7,8). The present study was prompted by
the successful management of a 14-year-old boy who had
been resuscitated from cardiac arrest during swimming and
was referred to our hospital. His baseline 12-lead electro-
cardiogram (ECG) showed borderline corrected QT inter-
val (QTc) (442 ms) (Fig. 1A), but epinephrine infusion
prolonged the QTc remarkably (585 ms), leading to spon-
taneously terminating torsade de pointes (TdP) (Fig. 1B).
The QTc interval was within normal range in his family
members examined (parents and two sisters). Molecular
screening for LQTS mutation was performed later, con-
firming the diagnosis of LQT1 syndrome. We designed a
study to perform a systematic evaluation of the diagnostic
value of epinephrine infusion in unmasking nonpenetrant
mutation carriers with LQT1 syndrome.
METHODS
Study population. Eleven families affected with LQT1
syndrome were entered into the present study (six KCNQ1
missense mutations, one splice mutation, and one deletion
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mutation). Among the eight mutations, five were in the core
domain (six families) and three in the C-terminal domains
(five families). Eleven families included 19 mutation carriers
(seven families) with a prolonged QTc interval of 460 ms
(Group I), 15 mutation carriers (seven families) with a
normal or borderline QTc of 460 ms (Group II), and 12
nonmutation carriers (eight families) (Group III). Fifteen
healthy volunteers were selected from doctors and nurses in
our hospital and entered as controls (Group IV). LQTS-
affected individuals were noted on the basis of electrocar-
diographic diagnostic criteria by Keating et al. (9), including
a QTc 470 ms in asymptomatic individuals and a QTc
440 ms for men and 460 ms for women associated with
one or more of the following: 1) stress-related syncope, 2)
documented TdP, or 3) family history of early sudden
cardiac death. The score of the LQTS was also calculated
using the diagnostic criteria by Schwartz et al. (10).
Recording of standard 12-lead ECGs. Genotyping of
LQTS was reviewed and approved by our Ethical Review
Committee, and written informed consent was obtained
from all patients, or their parents when the patients were
20 years of age. The epinephrine test was conducted as
part of clinical evaluation of the LQTS. Standard 12-lead
ECG was recorded with an FDX6521 (Fukuda Denshi Co.,
Tokyo, Japan) in the supine position without antiarrhyth-
mic medications including beta-blockers. These electrocar-
diographic data were digitized using analog-digital convert-
ers with a sampling rate of 1,000 samples/s/channel.
Measurement. Measurement of the electrocardiographic
parameters was performed in a blinded fashion as to
genotype status against five-averaged QRS complex by an
offline computer using the analysis program developed by
our institution. The Q-Tend interval was defined as the
interval between the QRS onset and the point at which the
isoelectric line intersected a tangential line drawn at the
minimum first derivative (dV/dt) point of the positive
T-wave or at the maximum dV/dt point of the negative
T-wave. When a bifurcated or secondary T-wave (patho-
logic U-wave) appeared, it was included as part of the
measurement of the Q-Tend interval, but a normal U-wave,
which was apparently separated from a T-wave, was not
included (11). The Q-Tpeak interval was defined as the
interval between the QRS onset and the peak of the positive
T-wave or the nadir of the negative T-wave. When the
T-wave had a biphasic or a notched configuration, peak of
the T-wave was defined as that of the dominant T deflec-
tion. The five QRS complexes were averaged first for each
lead. Then, the Q-Tend, Q-Tpeak and Tpeak-end (Q-
Tend minus Q-Tpeak) intervals, as an index of transmural
dispersion of repolarization, were measured automatically
from all 12-lead ECGs, corrected by Bazett’s method
(corrected Q-Tend [QTce], corrected Q-Tpeak [QTcp],
corrected Tpeak-end [Tcp-e]), and averaged among all
12-leads. As an index of spatial dispersion of repolarization,
dispersion of the QTce and the QTcp was defined as the
interval between the maximum and the minimum of the
QTce and the QTcp among 12-leads, respectively.
Epinephrine administration. A bolus injection of epi-
nephrine (0.1 g/kg), an alpha  beta-adrenergic agonist,
was immediately followed by continuous infusion (0.1
g/kg/min). The 12-lead ECG was continuously recorded
during sinus rhythm under baseline conditions and usually
for 5 min under epinephrine infusion. The effect of epi-
nephrine on both RR and QT intervals usually reached
steady-state conditions 2 to 3 min after the start of epineph-
rine. Epinephrine infusion for more than 5 min was
avoided, and electrocardiographic monitoring was contin-
ued for a further 5 min after epinephrine infusion for
possible occurrence of TdP. The electrocardiographic data
were collected under baseline conditions and at steady-state
conditions of epinephrine (3 to 5 min after the start of
epinephrine), and compared among the four groups. The
epinephrine test was performed in a blinded fashion as to
genotype status in 31 of 46 family members, because the 31
members were not genotyped at the epinephrine test.
Statistical analysis. Data are expressed as mean  SD,
except for those shown in the figures, which are expressed as
mean  SEM. Repeated-measures two-way analysis of
variance followed by Scheffe’s test was used to compare
measurements made before and after epinephrine, and to
compare differences between the groups (STATISTICA,
98 edition, StatSoft Inc., Tulsa, Oklahoma). Repeated-
measures one-way analysis of variance followed by Scheffe’s
test were used to compare changes () of the measurements
with epinephrine between the groups. Differences in fre-
quencies were analyzed by the chi-square test. A two-sided
p value 0.05 was considered significant.
RESULTS
Clinical and molecular diagnosis. Clinical characteristics
of the four groups are shown in Table 1. All 19 Group I
patients could be diagnosed as having LQTS by electrocar-
diographic diagnostic criteria; 18 patients had a score 4
(high probability of LQTS), and an average score of the 19
patients was 5.5  1.3 points (range 3 to 7.5 points). One
Group II patient could be diagnosed as having LQTS; all 15
Group II patients had a score2 and an average score of 0.7
Abbreviations and Acronyms
APD  action potential duration
ECG  electrocardiogram
IKs  slow component of the delayed rectifier
potassium current
INa  sodium current
INa-Ca  Na
/Ca2 exchange current
LQTS  long QT syndrome
QTc  corrected QT interval
QTce  corrected Q-Tend interval
QTcp  corrected Q-Tpeak interval
Tcp-e  corrected interval between Tpeak and Tend
TdP  torsade de pointes
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Figure 1. Twelve-lead electrocardiograms under baseline condition (A) and precordial electrocardiograms during epinephrine infusion (2 min after start of epinephrine) (B) in an LQT1 mutation carrier. The
mean corrected Q-Tend interval was dramatically prolonged by epinephrine, leading to spontaneously terminating torsade de pointes. 635
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 0.7 points (range 0 to 2 points). All 12 Group III patients
could not be diagnosed as having LQTS, and had a score
1 (0.7 0.5 points). All 15 Group IV controls had a QTc
of 440 ms and no symptoms. Therefore, the sensitivity
and specificity for identifying mutation carriers among the
family members and controls were 59% (20/34) and 100%
(27/27), respectively, by using the electrocardiographic di-
agnostic criteria of Keating et al. (9). They were 53%
(18/34) and 100% (27/27) when an LQTS score 4 was
used (10), and 59% (20/34) and 100% (27/27) when a score
2 was used (Table 2). Average penetrance in the 11 LQT1
families was 59% (20/34). Among the 34 mutation carriers
in Groups I and II, 15 patients were symptomatic (Group I,
14/19; Group II, 1/15) and 19 patients were asymptomatic.
Comparative influence of epinephrine in the four
groups. Figure 2 illustrates 12-lead ECGs under baseline
conditions and during epinephrine infusion in Group I and
Group II patients. In the Group I patients, both the mean
QTce and QTcp were prolonged (516 ms, 431 ms) and the
mean Tcp-e was increased (85 ms) under baseline condi-
tions (Fig. 2A). Epinephrine produced a marked prolonga-
tion in the mean QTce (586 ms), but a mild prolongation in
the mean QTcp (459 ms), resulting in a further increase in
the mean Tcp-e (127 ms) (Fig. 2B). Although the baseline
electrocardiographic parameters were normal in the Group
II patients (Fig. 2C), epinephrine prolonged both the mean
QTce (4353516 ms) and QTcp (3623420 ms), and
increased the mean Tcp-e (73396 ms) (Fig. 2D). Figure 3
illustrates 12-lead ECGs under baseline conditions and
during epinephrine infusion in Group III and Group IV
patients. The Group III patient is an older brother of the
Group II patient shown in Figures 2C and 2D. The baseline
electrocardiographic parameters were normal (Figs. 3A and
3C), and no significant changes were produced by epineph-
rine in both group patients (Figs. 3B and 3D). Figures 4A
through 4E show composite data of the electrocardio-
graphic parameters before and after epinephrine in the four
groups. The mean QTce, QTcp, and Tcp-e before epineph-
rine were significantly larger in Group I than in the other
three groups (Scheffe’s test value, p  0.005, Figs. 4A to
4C). Epinephrine significantly increased all the electrocar-
diographic parameters except the dispersion of the QTce in
Groups I and II (Scheffe’s test value, p  0.05), but did not
increase parameters in Groups III and IV. Therefore, all
electrocardiographic parameters after epinephrine were sig-
nificantly larger in Groups I and II (mutation carriers) than
those in Groups III (nonmutation carriers) and IV (con-
trols) (Scheffe’s test value, p  0.05, Figs. 4A to 4E). The
changes () in the mean QTce, QTcp, and Tcp-e with
epinephrine were not different between Groups I and II, but
they were significantly larger than those in Groups III and
IV (Scheffe’s test value, p  0.005, Figs. 5A to 5C). The
changes in the dispersion of the QTce and the QTcp with
epinephrine were not different among the four groups,
except for the change in the dispersion of the QTcp between
Groups I and III (Scheffe’s test value, p  0.05, Figs. 5D
and 5E). The sensitivity for differentiating mutation carriers
from nonmutation carriers and controls was substantially
Table 1. Clinical Characteristics of Groups I, II, III, and IV
Group I
(n  19)
Group II
(n  15)
Group III
(n  12)
Group IV
(n  15)
Age, yrs 27  18 22  17 31  18 28  16
Age  15 yrs (%) 7/19 (37%) 9/15 (60%) 3/12 (25%) 4/15 (27%)
Female gender (%) 14/19 (74%) 7/15 (47%) 8/12 (67%) 9/15 (60%)
Heart rate, beats/min 68  9 70  10 69  11 67  10
QTc, ms 507  31* 427  21 414  18 417  20
Syncope or aborted cardiac arrest (%) 14/19 (74%)* 1/15 (7%) (0%) (0%)
Beta-blockers (%) (0%) (0%) (0%) (0%)
Core domain mutation (%) 12/19 (63%) 6/15 (40%) NA NA
Values are mean  SD where indicated. *p  0.005 vs. Groups II, III and IV.
NA  not applicable; QTc  corrected QT interval.
Table 2. Diagnostic Accuracy of Clinical Parameters Before and After Epinephrine
Baseline Epinephrine
Sensitivity
(%)
Specificity
(%)
Sensitivity
(%)
Specificity
(%)
ECG criteria (8) 20/34 (59%) 27/27 (100%) 31/34 (91%) 27/27 (100%)
(1/15 [7%]) (12/15 [80%])
Score  4 (9) 18/34 (53%) 27/27 (100%) 25/34 (74%) 27/27 (100%)
(0/15 [0%]) (6/15 [40%])
Score  2 (9) 20/34 (59%) 27/27 (100%) 31/34 (91%) 27/27 (100%)
(2/15 [13%]) (12/15 [80%])
QTc  30ms NA NA 31/34 (91%) 27/27 (100%)
NA (13/15 [87%])
Number in parenthesis indicates the sensitivity in only 15 Group II patients.
ECG  electrocardiographic; NA  not applicable; QTc  an increase of mean corrected Q-Tend with epinephrine.
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Figure 2. Twelve-lead electrocardiograms under baseline conditions and during epinephrine infusion in Group I (A and B) and Group II (C and D) patients. Epinephrine markedly prolonged the mean
corrected Q-Tend in both Group I (5163586 ms) and Group II (4353516 ms) patients.
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Figure 3. Twelve-lead electrocardiograms under baseline conditions and during epinephrine infusion in Group III (A and B) and Group IV (C and D) patients. No significant changes were produced by
epinephrine in both Group III (4023394 ms) and Group IV (3813392 ms) patients.
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Figure 4. Composite data of the electrocardiographic parameters (A to E) and heart rate (F) before and after epinephrine in Groups I (closed circle), II
(open circle), III (open square), and IV (open triangle). *p  0.005 vs. Groups II, III, and IV; §p  0.005 vs. Groups III and IV; §§p  0.05 vs. Groups
III and IV; ¶p  0.005 vs. before; ¶¶p  0.05 vs. before.
Figure 5. Composite data of the changes () of the electrocardiographic parameters (A to E) and heart rate (F) with epinephrine in Groups I, II, III, and
IV. *p  0.005 vs. Groups III and IV; **p  0.05 vs. Group III.
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improved by epinephrine test without the expense of spec-
ificity (100%, 27/27): 91% (31/34) by using the electrocar-
diographic diagnostic criteria or when an LQTS score 2
was used, and 74% (25/34) when a score 4 was used. An
increase of mean QTce with epinephrine 30 ms also
improved the sensitivity to 91% (31/34) without the expense
of the specificity (Table 2, Fig. 5A). Even if we excluded the
Group I patients who had a clear diagnosis of LQTS before
epinephrine and analyzed the sensitivity only in Group II
patients, the sensitivity was improved with the epinephrine
test: from 7% (1/15) to 80% (12/15) by using the electro-
cardiographic diagnostic criteria, from 0% (0/15) to 40%
(6/15) when an LQTS score 4 was used, from 13% (2/15)
to 80% (12/15) when a score 2 was used, and to 87%
(13/15) when an increase of mean QTce with epinephrine
30 ms was used (parenthesis in Table 2). The heart rate
before and after epinephrine and the increases of heart rate
were not different among the four groups (Figs. 4F and 5F).
Influence of epinephrine between symptomatic and
asymptomatic mutation carriers. The electrocardio-
graphic parameters and the heart rate before and after
epinephrine were compared between 15 symptomatic pa-
tients and 19 asymptomatic mutation carriers in Groups I
and II. The mean QTce, QTcp, and Tcp-e both before and
after epinephrine were significantly greater in the 15 symp-
tomatic patients than in the 19 asymptomatic mutation
carriers (Scheffe’s test value, p  0.05), whereas neither
dispersion of the QTce nor dispersion of the QTcp were
different between the two groups. Epinephrine significantly
increased all the electrocardiographic parameters except the
dispersion of the QTce in both symptomatic and asymp-
tomatic mutation carriers (Scheffe’s test value, p  0.05).
Figure 6 illustrates composite data of the changes () of the
electrocardiographic parameters and the heart rate with
epinephrine in the 15 symptomatic patients and the 19
asymptomatic mutation carriers. The prolongation of the
mean QTce with epinephrine was significantly greater in
the 15 symptomatic patients than in the 19 asymptomatic
mutation carriers (Scheffe’s test value, p  0.05), whereas
the changes in the other parameters were not different
between the two groups.
Complications. Spontaneously terminating TdP was in-
duced by epinephrine infusion (2 min after the start of
epinephrine) in one Group II patient (Fig. 1), and sponta-
neous premature ventricular contractions were induced in
one Group I patient.
DISCUSSION
The present study demonstrates that epinephrine infusion is
a provocative test that greatly increases the sensitivity of
electrocardiographic diagnosis of LQT1 syndrome, one of
the two most common variants of LQTS, thus providing
clinicians with a powerful tool for improving appropriate
diagnosis and management of LQTS.
Low penetrance in the LQT1 syndrome. The hypothesis
that electrocardiographic diagnosis could miss patients af-
fected by LQTS had already been proposed before the
Figure 6. Composite data of the changes () of the electrocardiographic parameters (A to E) and heart rate (F) with epinephrine in 15 symptomatic patients
(Sym) and 19 asymptomatic mutation carriers (Asym) in Groups I and II. *p  0.05 vs. Asym.
640 Shimizu et al. JACC Vol. 41, No. 4, 2003
Epinephrine in LQT1 Syndrome February 19, 2003:633–42
genetic bases of the disease were known (12). These initial
observations were based on the evidence that syncopal
events could occur among family members with a “normal”
QT interval. Several years later, Vincent et al. (13) reported
that five (6%) of 82 mutation carriers from three LQT1
families had a normal QT interval. More recently, Priori et
al. (5) have demonstrated a very low penetrance (38%, 9/24)
in nine families with only one individual clinically affected
with LQTS. In the present study, the average penetrance
was 59% (20/34) among 11 LQT1 families. The sensitivity
and specificity for identifying mutation carriers were 59%
and 100% by using the electrocardiographic diagnostic
criteria or when an LQTS score2 was used, and they were
53% and 100% when a score 4 was used. Our data are in
agreement with other reports demonstrating a 100% spec-
ificity and 53% sensitivity for diagnosis of high probability
of LQTS (14). Overall, these findings strongly point to the
need of novel tools to unveil nonpenetrant mutation carriers
of LQTS.
Usefulness of epinephrine infusion in unmasking LQT1
mutation carriers. Provocative tests using catecholamine
or exercise testing have long been considered to unmask
some forms of congenital LQTS (6). Recent preliminary
data by Ackerman et al. (8) have suggested the usefulness of
an epinephrine test to unveil concealed LQT1 syndrome.
This study provides systematic evaluation of the efficacy of
epinephrine provocative challenge to unmask silent forms of
LQTS in a group of genetically characterized individuals.
Our data demonstrate that intravenous administration of
epinephrine significantly improves the sensitivity of electro-
cardiographic diagnosis of LQTS in carriers of KCNQ1
defects. Because KCNQ1 is one of the two most common
forms of congenital LQTS, this provocative challenge could
be applied to a large number of individuals suspected to be
affected by this variant of the disease. On the basis of current
data, probands of congenital LQTS who had cardiac events
during exercise and emotion (4), and particularly during
swimming (2,3), have a high probability of being affected by
KCNQ1 genetic defects. Accordingly, all their family mem-
bers become likely candidates for epinephrine provocative
challenge. The identification of affected individuals with
normal electrocardiographic phenotype is of major impor-
tance, as it would enable limiting exposure of these individ-
uals to potentially dangerous conditions such as participa-
tion in competitive sports and use of drugs known to
prolong repolarization, thus reducing the risk of life-
threatening cardiac arrhythmias (15). However, it goes
without saying that an epinephrine provocative test should
only be done by cardiologists under enough preparation of
intravenous beta-blockers as well as a direct cardioverter for
unintentionally induced ventricular fibrillation. Darbar et al.
(16) reported that the QTc was increased in lead II (but not
in lead V3) by epinephrine infusion even in normal controls,
and suggested that this was due to increasing calcium
current as well as hypokalemia induced by epinephrine. In
this study, the QTce was not prolonged by epinephrine in
Group III (nonmutation carrier) and Group IV (controls),
probably as a result of the measurement of averaged QTce
among all 12-leads as well as too-short epinephrine infusion
(5 min) to induce hypokalemia (17).
Mechanism of influence of epinephrine in LQT1 muta-
tion carriers. Both experimental and clinical studies have
suggested a differential response of action potential duration
(APD) and QT interval to sympathetic stimulation among
LQT1, LQT2, and LQT3 (7,8,18). Persistent and para-
doxical prolongation of APD and QT interval at steady-
state conditions of catecholamines was reported in LQT1
syndrome. Under normal conditions, beta-adrenergic stim-
ulation is expected to increase net outward repolarizing
current, owing to larger increase of outward currents,
including Ca2-activated slow component of the delayed
rectifier potassium current (IKs) and Ca
2-activated chlo-
ride current, than that of an inward current, Na/Ca2
exchange current (INa-Ca), resulting in an abbreviation of
APD and QT interval. A defect in IKs in the LQT1
syndrome could account for failure of beta-adrenergic stim-
ulation to abbreviate APD and QT interval, resulting in a
persistent and paradoxical QT prolongation under sympa-
thetic stimulation (18). In LQT2 syndrome, catecholamines
are reported to initially prolong but then abbreviate APD
and QT interval, probably because of an initial augmenta-
tion of INa-Ca and a subsequent stimulation of IKs. In
contrast to the LQT1 and LQT2 syndromes, cat-
echolamines are reported to constantly abbreviate APD and
QT interval as a result of a stimulation of IKs in the LQT3
syndrome, because an inward late sodium current (INa) was
augmented in this genotype. Taken together with the data
in the present study, the epinephrine test may be applied not
only for unmasking silent mutation carriers with LQT1
syndrome but also for predicting genotype.
Symptomatic versus asymptomatic mutation carriers. In
this study, the mean QTce, QTcp, and Tcp-e under the
baseline conditions were significantly greater in the 15
symptomatic patients than in the 19 asymptomatic muta-
tion carriers, consistent with previous large family studies
without molecular diagnosis (12,19). Moreover, the
epinephrine-induced prolongation of the mean QTce was
significantly larger in the 15 symptomatic patients. This
indicates a higher vulnerability of ventricular repolarization
to sympathetic stimulation in symptomatic patients, al-
though unknown factors may influence this phenomenon.
The data also suggest that the epinephrine test may detect
high-risk mutation carriers by the degree of QTc prolon-
gation. In reverse, epinephrine-induced QTc prolongation
was smaller in asymptomatic mutation carriers, indicating
that the epinephrine test does not exert as great an effect to
unveil mutation carriers in asymptomatic family members.
However, epinephrine-induced prolongation of the mean
QTce was 30 ms in all but two asymptomatic mutation
carriers, and was clearly greater than those in either non-
mutation carriers or normal controls. Prospective study
using 30-ms cutoff with epinephrine challenge will be
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needed in order to conclude the diagnostic value of the
epinephrine test.
Dispersion of repolarization. The mean QTce was the
most sensitive parameter to epinephrine; however, the mean
Tcp-e was also increased by epinephrine only in the muta-
tion carriers, suggesting that sympathetic stimulation in-
creases transmural dispersion of repolarization (20), leading
to arrhythmogenesis in the LQTS with KCNQ1 defects. In
contrast, the dispersion of the QTce, as an index of spatial
dispersion of repolarization, was not significantly increased
by epinephrine in Groups I and II (mutation carriers), and
the changes in the dispersion of the QTce with epinephrine
were not different among the four groups. These data may
be explained by a recent elegant study using computer
simulation conducted by Burnes et al. (21), in which they
suggested that regional heterogeneity of repolarization was
not reflected in QT dispersion recorded from the body
surface ECG.
Study limitations. First, the numbers of families and of
individuals in the present study are relatively small, and all
patients are the same ethnic origin (Japanese). Because the
issue of ethnicity as a modulator of genetically determined
disease is receiving increasing attention, our data may or
may not be applicable to other ethnicities.
Second, although peak of the T-wave was defined as that
of the dominant T deflection when the T-wave had a
biphasic or a notched configuration, it is still unclear which
peak of the biphasic or notched T-wave reflects the repo-
larization of epicardial action potential. Further basic stud-
ies will be needed to conclude the cellular basis for complex
T-waves.
Third, we used Bazett’s formula for correction of heart
rate. Bazett’s formula is derived from normal individuals,
and its use at higher heart rate is likely to lead to an
overestimation of the QTc, thus contributing to the increase
in sensitivity, which should be taken into account to
interpret data in this kind of study.
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